This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.

Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition. An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features: a new eight-page color insert 200 color and black-and-white illustrations reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field New topics in Myelodysplastic Syndrome include: del(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome the reborn DNA methyltransferase inhibiting nucleoside analogs the diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features the role of mitochondria and the potential importance of iron overload in MDS global genomics approaches, such as cDNA expression arrays, array-based comparative genomic hybridization, and single nucleotide polymorphism array the role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD other disease-associated alterations, such as abnormalities of B lymphocyte populations in MD three recently approved drugs: azacitidine, lenalidomide, and decitabine